EP Patent

EP4244216A1 — Ligands of prostate specific membrane antigen (psma) containing heteroaromatic linker building blocks

Assigned to ABX Advanced Biochemical Compounds GmbH · Expires 2023-09-20 · 3y expired

What this patent protects

The present invention relates to novel compounds that bind to the prostate-specific membrane antigen (PSMA)-binding and their use in the diagnosis and treatment of certain diseases where PSMA is upregulated.

USPTO Abstract

The present invention relates to novel compounds that bind to the prostate-specific membrane antigen (PSMA)-binding and their use in the diagnosis and treatment of certain diseases where PSMA is upregulated.

Drugs covered by this patent

lutetium-lu-177-vipivotide-tetraxetan (LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN)

Patent Metadata

Patent number: EP4244216A1
Jurisdiction: EP
Classification: —
Expires: 2023-09-20
Drug substance claim: No
Drug product claim: No
Assignee: ABX Advanced Biochemical Compounds GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.